{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:20:32Z","timestamp":1782483632870,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020964","name":"Fusion Oriented REsearch for disruptive Science and Technology","doi-asserted-by":"publisher","award":["JPMJFR204J"],"award-info":[{"award-number":["JPMJFR204J"]}],"id":[{"id":"10.13039\/501100020964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K02586"],"award-info":[{"award-number":["24K02586"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Gastric-type adenocarcinoma (GAS) of the uterine cervix is a rare and aggressive subtype of cervical adenocarcinoma characterized by intrinsic resistance to chemotherapy and poor clinical outcomes due to the lack of effective treatment options. To address this critical unmet need, we established a novel GAS-derived cell line, KGAS, from ascitic fluid collected from a patient with recurrent GAS. Short tandem repeat (STR) analysis confirmed the genetic identity between the primary tumor and the cell line. Upon transplantation into immunocompromised mice, KGAS cells formed tumors that expressed Claudin-18 and MUC6, clinically recognized markers of GAS. Furthermore, KGAS cells exhibited marked resistance to paclitaxel and carboplatin, showing significantly reduced growth inhibition compared to HeLa cells. We also established a paclitaxel- and carboplatin-resistant subline, rKGAS, and performed microRNA (miRNA) sequencing to explore the molecular basis of acquired chemoresistance. Seventeen differentially expressed miRNAs were identified between KGAS and rKGAS cells. Upregulated miRNAs in rKGAS were predicted to target oncogenes such as BCL2, MET, SIRT1, and VEGFA, whereas downregulated miRNAs were associated with tumor suppressor genes, including IGF1R, TNFAIP3, and MTOR. The KGAS and rKGAS cell lines represent valuable preclinical models for elucidating the molecular mechanisms of chemoresistance and malignant progression in cervical GAS, and may contribute to the development of novel therapeutic strategies for this challenging cancer subtype.<\/jats:p>","DOI":"10.1007\/s13577-025-01286-9","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:58:04Z","timestamp":1757912284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Establishment of KGAS, a cell line derived from gastric-type adenocarcinoma of the uterine cervix"],"prefix":"10.1007","volume":"38","author":[{"given":"Hiroaki","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Asano-Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"6","key":"1286_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1286_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/gyno.2000.5826","volume":"78","author":"HO Smith","year":"2000","unstructured":"Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States\u2013a 24-year population-based study. Gynecol Oncol. 2000;78(2):97\u2013105. https:\/\/doi.org\/10.1006\/gyno.2000.5826.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/his.13995","volume":"76","author":"KJ Park","year":"2020","unstructured":"Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology. 2020;76(1):112\u201327. https:\/\/doi.org\/10.1111\/his.13995.","journal-title":"Histopathology"},{"issue":"5","key":"1286_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/01.pas.0000213434.91868.b0","volume":"31","author":"A Kojima","year":"2007","unstructured":"Kojima A, Mikami Y, Sudo T, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31(5):664\u201372. https:\/\/doi.org\/10.1097\/01.pas.0000213434.91868.b0.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1286_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ygyno.2019.01.022","volume":"153","author":"S Nishio","year":"2019","unstructured":"Nishio S, Mikami Y, Tokunaga H, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix - an aggressive tumor with a poor prognosis: a multi-institutional study. Gynecol Oncol. 2019;153(1):13\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2019.01.022.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1286_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/his.13977","volume":"76","author":"IA Cree","year":"2020","unstructured":"Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76(1):151\u20136. https:\/\/doi.org\/10.1111\/his.13977.","journal-title":"Histopathology"},{"issue":"1","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/igc.0000000000001145","volume":"28","author":"A Kojima","year":"2018","unstructured":"Kojima A, Shimada M, Mikami Y, et al. Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the Sankai Gynecology Study Group. Int J Gynecol Cancer. 2018;28(1):99\u2013106. https:\/\/doi.org\/10.1097\/igc.0000000000001145.","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41379-019-0305-x","volume":"32","author":"S Garg","year":"2019","unstructured":"Garg S, Nagaria TS, Clarke B, et al. Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing. Mod Pathol. 2019;32(12):1823\u201333. https:\/\/doi.org\/10.1038\/s41379-019-0305-x.","journal-title":"Mod Pathol"},{"issue":"7","key":"1286_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/carcin\/bgz168","volume":"41","author":"J Jung","year":"2020","unstructured":"Jung J, Kim S, An HT, Ko J. \u03b1-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer. Carcinogenesis. 2020;41(7):940\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgz168.","journal-title":"Carcinogenesis"},{"issue":"19","key":"1286_CR10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/jco.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33(19):2129\u201335. https:\/\/doi.org\/10.1200\/jco.2014.58.4391.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1286_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12964-024-01957-4","volume":"22","author":"M Liaghat","year":"2024","unstructured":"Liaghat M, Ferdousmakan S, Mortazavi SH, et al. The impact of epithelial-mesenchymal transition (EMT) induced by metabolic processes and intracellular signaling pathways on chemo-resistance, metastasis, and recurrence in solid tumors. Cell Commun Signal. 2024;22(1):575. https:\/\/doi.org\/10.1186\/s12964-024-01957-4.","journal-title":"Cell Commun Signal"},{"issue":"7702","key":"1286_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/d41586-018-04403-x","volume":"556","author":"EW Thompson","year":"2018","unstructured":"Thompson EW, Nagaraj SH. Transition states that allow cancer to spread. Nature. 2018;556(7702):442\u20134. https:\/\/doi.org\/10.1038\/d41586-018-04403-x.","journal-title":"Nature"},{"issue":"2","key":"1286_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/gyno.2001.6369","volume":"83","author":"M Wobus","year":"2001","unstructured":"Wobus M, Kuns R, Wolf C, et al. CD44 mediates constitutive type I receptor signaling in cervical carcinoma cells. Gynecol Oncol. 2001;83(2):227\u201334. https:\/\/doi.org\/10.1006\/gyno.2001.6369.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"1286_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s001099900038","volume":"77","author":"M Balzar","year":"1999","unstructured":"Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17\u20131A antigen (Ep-CAM). J Mol Med (Berl). 1999;77(10):699\u2013712. https:\/\/doi.org\/10.1007\/s001099900038.","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc2562","volume":"9","author":"CL Brooks","year":"2009","unstructured":"Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 2009;9(2):123\u20138. https:\/\/doi.org\/10.1038\/nrc2562.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1286_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871\u201382. https:\/\/doi.org\/10.1038\/nrc3627.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1286_CR17","first-page":"1782","volume":"26","author":"L Han","year":"2021","unstructured":"Han L. MiR-99a inhibits proliferation and migration of cervical cancer cells by targeting IGF1R. J buon. 2021;26(5):1782\u20138.","journal-title":"J buon"},{"issue":"3","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","volume":"142","author":"CR Maroun","year":"2014","unstructured":"Maroun CR, Rowlands T. The met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014;142(3):316\u201338. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.014.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"1286_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152471","volume":"215","author":"B Du","year":"2019","unstructured":"Du B, Liu M, Li C, et al. The potential role of TNFAIP3 in malignant transformation of gastric carcinoma. Pathol Res Pract. 2019;215(8):152471. https:\/\/doi.org\/10.1016\/j.prp.2019.152471.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"1286_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3001","volume":"11","author":"G Francia","year":"2011","unstructured":"Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011;11(2):135\u201341. https:\/\/doi.org\/10.1038\/nrc3001.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1286_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12935-024-03420-3","volume":"24","author":"S Taeb","year":"2024","unstructured":"Taeb S, Rostamzadeh D, Amini SM, et al. Micrornas targeted mTOR as therapeutic agents to improve radiotherapy outcome. Cancer Cell Int. 2024;24(1):233. https:\/\/doi.org\/10.1186\/s12935-024-03420-3.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1286_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338\u201350. https:\/\/doi.org\/10.1038\/nrclinonc.2012.61.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1\u20132","key":"1286_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/sj.neo.7900079","volume":"2","author":"CH Contag","year":"2000","unstructured":"Contag CH, Jenkins D, Contag PR, Negrin RS. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia. 2000;2(1\u20132):41\u201352. https:\/\/doi.org\/10.1038\/sj.neo.7900079.","journal-title":"Neoplasia"},{"issue":"1","key":"1286_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","volume":"163","author":"CP Day","year":"2015","unstructured":"Day CP, Merlino G, Van Dyke T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell. 2015;163(1):39\u201353. https:\/\/doi.org\/10.1016\/j.cell.2015.08.068.","journal-title":"Cell"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01286-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:02:24Z","timestamp":1757955744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01286-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01286-9","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committee of the Kurume University Hospital (Fukuoka, Japan) approved the use of clinical materials for this study (approval No. 22131). All animal procedures were reviewed and approved by the Nagoya University Institutional Animal Experimentation Committee (Approval No. 240332). In addition, they complied with the ARRIVE guidelines and were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986, and related guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was provided by the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"159"}}